Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP749179.RAzzWy_2UWdpiODqBzIoXbZwSDZbqkcs-tl29pcMaXGbM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP749179.RAzzWy_2UWdpiODqBzIoXbZwSDZbqkcs-tl29pcMaXGbM130_assertion type Assertion NP749179.RAzzWy_2UWdpiODqBzIoXbZwSDZbqkcs-tl29pcMaXGbM130_head.
- NP749179.RAzzWy_2UWdpiODqBzIoXbZwSDZbqkcs-tl29pcMaXGbM130_assertion description "[During a median follow-up period of 55 months (range, 6 to 81 months), the subgroup of patients with hormone receptor-negative cancer and without TOP2A amplification showed the worst survival (relapse-free survival: hazard ratio (HR) = 0.29, 95% confidence interval (95% CI), 0.13 to 0.65, P = 0.001; and overall survival: HR = 0.28, 95% CI, 0.10 to 0.76, P = 0.008).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP749179.RAzzWy_2UWdpiODqBzIoXbZwSDZbqkcs-tl29pcMaXGbM130_provenance.
- NP749179.RAzzWy_2UWdpiODqBzIoXbZwSDZbqkcs-tl29pcMaXGbM130_assertion evidence source_evidence_literature NP749179.RAzzWy_2UWdpiODqBzIoXbZwSDZbqkcs-tl29pcMaXGbM130_provenance.
- NP749179.RAzzWy_2UWdpiODqBzIoXbZwSDZbqkcs-tl29pcMaXGbM130_assertion SIO_000772 21288332 NP749179.RAzzWy_2UWdpiODqBzIoXbZwSDZbqkcs-tl29pcMaXGbM130_provenance.
- NP749179.RAzzWy_2UWdpiODqBzIoXbZwSDZbqkcs-tl29pcMaXGbM130_assertion wasDerivedFrom befree-20150227 NP749179.RAzzWy_2UWdpiODqBzIoXbZwSDZbqkcs-tl29pcMaXGbM130_provenance.
- NP749179.RAzzWy_2UWdpiODqBzIoXbZwSDZbqkcs-tl29pcMaXGbM130_assertion wasGeneratedBy ECO_0000203 NP749179.RAzzWy_2UWdpiODqBzIoXbZwSDZbqkcs-tl29pcMaXGbM130_provenance.